FY2029 Earnings Estimate for Q32 Bio Issued By HC Wainwright

Q32 Bio Inc. (NASDAQ:QTTB) – Stock analysts at HC Wainwright issued their FY2029 earnings per share estimates for Q32 Bio in a report released on Wednesday, February 25th. HC Wainwright analyst J. Pantginis forecasts that the company will earn ($0.18) per share for the year. HC Wainwright currently has a “Buy” rating and a $13.00 target price on the stock. The consensus estimate for Q32 Bio’s current full-year earnings is ($12.32) per share. HC Wainwright also issued estimates for Q32 Bio’s FY2030 earnings at $0.11 EPS.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Q32 Bio in a research note on Friday, January 9th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $14.00.

Q32 Bio Price Performance

NASDAQ:QTTB opened at $4.73 on Thursday. The firm has a market capitalization of $58.18 million, a P/E ratio of -1.37 and a beta of 0.16. The business has a 50 day simple moving average of $3.75 and a 200 day simple moving average of $2.86. Q32 Bio has a 12-month low of $1.35 and a 12-month high of $6.37.

Insider Activity at Q32 Bio

In other Q32 Bio news, CEO Jodie Pope Morrison sold 22,506 shares of the business’s stock in a transaction on Tuesday, December 2nd. The stock was sold at an average price of $3.46, for a total transaction of $77,870.76. Following the completion of the transaction, the chief executive officer owned 99,000 shares in the company, valued at approximately $342,540. The trade was a 18.52% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Lee Kalowski sold 9,072 shares of the stock in a transaction on Tuesday, December 2nd. The stock was sold at an average price of $3.46, for a total value of $31,389.12. Following the completion of the transaction, the chief financial officer directly owned 39,938 shares of the company’s stock, valued at approximately $138,185.48. The trade was a 18.51% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 40.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On Q32 Bio

Several institutional investors have recently bought and sold shares of QTTB. HRT Financial LP grew its position in Q32 Bio by 66.5% in the 4th quarter. HRT Financial LP now owns 24,698 shares of the company’s stock valued at $81,000 after buying an additional 9,862 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of Q32 Bio in the 2nd quarter worth approximately $25,000. Geode Capital Management LLC boosted its holdings in shares of Q32 Bio by 19.9% in the fourth quarter. Geode Capital Management LLC now owns 106,113 shares of the company’s stock valued at $352,000 after acquiring an additional 17,617 shares in the last quarter. ADAR1 Capital Management LLC bought a new position in shares of Q32 Bio in the fourth quarter valued at approximately $66,000. Finally, XTX Topco Ltd acquired a new position in shares of Q32 Bio during the fourth quarter valued at approximately $68,000. Institutional investors and hedge funds own 31.32% of the company’s stock.

Q32 Bio Company Profile

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.